3653 results for «358»
3653 results
PRISM-PCI - From clarity to cure
20 May 2026 – From EuroPCR 2026
PRISM-PCI offers cutting-edge imaging innovations and treatment strategies aimed at optimizing complex PCI procedures. This session explores the 'leave nothing behind' concept with thin-strut bioresorbable scaffolds and sirolimus drug-coated balloons, updates on ultra thin-strut DES platforms, including the SORT OUT XII trial, and introduces a comprehensive...
TAVI vs. surgery - Are the latest long-term data creating a dilemma for aortic stenosis patients?
21 May 2026 – From EuroPCR 2026
This session critically evaluates the latest long-term data comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). It explores differing perspectives between surgeons and interventional cardiologists regarding valve durability and lifetime management, fostering a high-quality debate to achieve consensus within Heart Team discussions...
CathWorks FFRangio: from clinical data to advanced patient care
21 May 2026 – From EuroPCR 2026
Explore the clinical value of the CathWorks FFRangio system through the lens of the ALL-RISE randomised controlled trial and its implications for daily practice. By reviewing the trial’s primary and secondary endpoints, examine how FFRangio may influence diagnostic assessment, treatment planning, and clinical decision-making in patients...
The continuum of valvular heart disease: a lifetime management approach
21 May 2026 – From EuroPCR 2026
This session offers a comprehensive perspective on valvular heart disease through the lens of lifetime management, highlighting the need for strategic planning across aortic, mitral, and tricuspid interventions, illustrating how treating one valve can influence the progression and management of others. Gain insights into optimal timing...
Renal denervation in China: momentum, insights, and evolution
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session highlights the rapidly evolving clinical experience of renal denervation (RDN) in China following regulatory approval, with a focus on real-world practice and programme development.
It reviews how structured, patient-centred hypertension pathways are being integrated with RDN, alongside practical strategies for managing complex renal...
Navigating high-thrombus burden in ACS: precision aspiration thrombectomy with CAT RX
21 May 2026 – From EuroPCR 2026
This session explores the challenges of managing high thrombus burden in patients with acute coronary syndromes (ACS), with a focus on precision aspiration thrombectomy using the CAT RX device. Through case-based examples, it provides practical insights into procedural techniques and examines the role of CAT RX...
The metal-free strategy: shaping the new era of hybrid vessel restoration with DCB and BRS
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the emerging metal-free strategy in coronary intervention, combining drug-coated balloons (DCB) and bioresorbable scaffolds (BRS) to support a “leave-nothing-behind” approach to vessel restoration.
It focuses on lesion preparation, scaffold sizing and deployment, and the integration of hybrid therapies to optimise procedural outcomes....
Rethinking stentless PCI strategy - Improving outcomes with Bioadaptor
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores contemporary PCI strategies through the concept of stentless intervention using the Bioadaptor device in complex coronary disease.
It highlights the bioadaptive design features of Bioadaptor and reviews the supporting clinical evidence, with a focus on how this technology may influence procedural outcomes.
The...
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...
Author
Author
World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!
29 Sep 2023
Global burden of Cardiovascular Disease
Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...
Author
The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030
29 Aug 2021
Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.
Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
